Sonoma Biotherapeutics Risk Report
Explore Sonoma Biotherapeutics across six non‑financial risk dimensions:ESG, Workforce, News & Media, Cybersecurity, Legal & Regulatory, Operational. Unlock the full report, original sources and timelines, and enable continuous monitoring.
Summary
📜 Innovation & R&D
Sonoma Biotherapeutics has demonstrated significant achievements in innovation and research, particularly in the development of Treg cell therapies. The company's collaboration with Regeneron to advance therapeutic solutions for autoimmune diseases is a crucial step towards pioneering treatments. Recently, Sonoma has focused efforts on expanding its infrastructure to support ongoing R&D initiatives.
- On 🗓 March 28, 2023, Sonoma Biotherapeutics and Regeneron announced a collaboration to discover, develop, and commercialize Treg cell therapies.
- On 🗓 February 11, 2024, the company raised $105 million aimed at tackling inflammation through innovative treatments.
- Sonoma leased a significant facility on 🗓 August 24, 2022, to expand its life science capabilities.
- The $45 million milestone payment from Regeneron reported on 🗓 September 4, 2024, underscores the progress in their joint endeavor.
🏅 Awards & Recognition
Sonoma Biotherapeutics has garnered prestigious acknowledgment in the scientific community, marking milestones in leadership and advanced therapy efforts. This recognition further validates the company's strategic direction and contribution to medical research.
- Co-founder Jeffrey Bluestone was elected to the National Academy of Sciences on 🗓 May 4, 2023, highlighting his influential work in the field.
Profile
News & Media
Real‑time aggregation of trusted sources tracking company‑related events with sentiment and topic tags for rapid risk triage.
Sign up to unlock Sonoma Biotherapeutics’s complete news feed with sentiment and topic tags.
View Full ReportEntity List
Continuous third‑party screening across global sanctions, enforcement, and watchlist sources with unified entity resolution and real‑time alerts.
| Name | Issuer | Status |
|---|---|---|
| ACF List of War Enablers | Anti-Corruption Foundation | |
| African Development Bank Debarred Entities | African Development Bank Group | |
| Argentina Members of Parliament | Honorable Cámara de Diputados de la Nación Argentina | |
| Argentina RePET Sanctions | Ministerio de Justicia | |
| Armenia Public Officials and Associates | Hetq Online | |
| Asian Development Bank Sanctions | Asian Development Bank | |
| Australian Sanctions Consolidated List | Department of Foreign Affairs and Trade | |
| Democratic People's Republic Of Korea (North Korea) Sanctions Regime | Department of Foreign Affairs and Trade | |
| Former Federal Republic Of Yugoslavia Sanctions Regime | Department of Foreign Affairs and Trade | |
| Iran Sanctions Regime | Department of Foreign Affairs and Trade |
Sign up to unlock Sonoma Biotherapeutics’s sanctions, enforcement, and watchlist risk profile.
View Full ReportESG
Verification of declared ESG commitments and certifications with evidence links, score signals, and status updates across E, S, and G.
| Name | Status |
|---|---|
| Sustainable Finance Disclosure Regulation | |
| Global Reporting Initiative Standards | |
| EU Taxonomy Regulation | |
| EU Corporate Sustainability Reporting Directive | |
| California Transparency in Supply Chains Act | |
| EU Non-Financial Reporting Directive | |
| ISO 14001 | |
| Sustainability Accounting Standards Board Standards | |
| Task Force on Climate-related Financial Disclosures | |
| UN Guiding Principles on Business and Human Rights |
Sign up to unlock Sonoma Biotherapeutics’s ESG commitments, certifications, and controversy signals.
View Full ReportCybersecurity
Verification of adherence to recognized security standards, mapping control coverage and gaps affecting third‑party and supply‑chain risk.
| Certification | Status |
|---|---|
| General Data Protection Regulation | |
| Digital Operational Resilience Act | |
| Cybersecurity Maturity Model Certification | |
| NIST Cybersecurity Framework | |
| NIST 800-53 Revision 5 | |
| California Consumer Privacy Act | |
| ISO/IEC 27001 | |
| Health Insurance Portability and Accountability Act | |
| Payment Card Industry Data Security Standard | |
| Federal Information Security Modernization Act |
Sign up to unlock Sonoma Biotherapeutics’s security standards, control gaps, and exposure risks.
View Full ReportGet Sonoma Biotherapeutics's full Non-Financial Risk Report
By signing up, you agree to our Terms and Privacy Policy.